Clinical-alimentary tractLactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles
Section snippets
Study population
Patients were recruited from gastroenterology clinics at Cork University Hospital and by direct advertisement on the university campus and in a local newspaper. Individuals aged between 18 and 75 years who satisfied Rome II criteria for the diagnosis of IBS3 and in whom organic gastrointestinal diseases, including inflammatory bowel disease, and clinically significant systemic diseases had been excluded were considered for inclusion in the study. Pregnant women, individuals with known lactose
Subjects
A total of 80 subjects were enrolled in the study. Two subjects (1 randomized to B infantis 35624 and 1 to placebo) were subsequently found to have taken antibiotics from the beginning of the treatment phase and were therefore determined to be nonevaluable. A further 3 subjects dropped out before the treatment phase. Therefore, 75 subjects provided some evaluable data. Of these, 3 subjects took an antibiotic during the course of the study; only data up to the commencement of antibiotic use were
Discussion
In this study, we compared, for the first time, the effects of 2 probiotic strains on symptoms in patients with IBS. We have shown superiority for bifidobacterium over both a lactobacillus and placebo for each of the cardinal symptoms of IBS and for a composite score. These symptomatic benefits were associated with parallel trends in a quality-of-life measure developed specifically for IBS.64 Furthermore, this therapy was well tolerated and free of significant adverse events. Interestingly,
References (86)
- et al.
AGA technical review on irritable bowel syndrome
Gastroenterology
(2002) Management of the irritable bowel syndrome
Gastroenterology
(2001)Pharmacologic therapy for the irritable bowel syndrome
Am J Gastroenterol
(2003)- et al.
Evolving pathophysiological models of functional gastrointestinal disorders
Gastroenterology
(2002) - et al.
Irritable bowel syndrome—post-salmonella infection
J Infect
(1994) Estimating the importance of infection in IBS
Am J Gastroenterol
(2003)- et al.
Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS
Gastroenterology
(2003) A case for an immunological basis for irritable bowel syndrome
Gastroenterology
(2002)- et al.
Activation of the mucosal immune system in irritable bowel syndrome
Gastroenterology
(2002) - et al.
Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome
Gastroenterology
(2002)
Eradication of small bowel bacterial overgrowth reduces symptoms of irritable bowel syndrome
Am J Gastroenterol
Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndromea double-blind, randomized, placebo-controlled study
Am J Gastroenterol
High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal
Am J Gastroenterol
Small bowel bacterial overgrowth, celiac disease and IBSwhat are the associations?
Am J Gastroenterol
The immunomodulation of enteric neuromuscular functionimplications for motility and inflammatory disorders
Gastroenterology
Probiotics in the third millennium
Dig Liver Dis
Abnormal colonic fermentation in irritable bowel syndrome
Lancet
Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome
Am J Gastroenterol
Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea
Res Microbiol
Further validation of the IBS-QOLa disease-specific quality-of-life questionnaire
Am J Gastroenterol
The role of probiotic cultures in the control of gastrointestinal health
J Nutr
Probiotics in antibiotic-associated diarrhoea
Dig Liver Dis
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis
Gastroenterology
DNA from probiotic bacteria modulates murine and human epithelial and immune function
Gastroenterology
Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome
Gastroenterology
Lactobacillus farciminis treatment reduces sensitivity to rectal distension in ratsinvolvement of nitric oxide
Gastroenterology
Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat
Gastroenterology
An evidence-based approach to the management of irritable bowel syndrome in North America
Am J Gastroenterol
Functional bowel disorders and functional abdominal pain
Gut
Irritable bowel syndrome in general practiceprevalence, characteristics, and referral
Gut
The prevalence, patterns and impact of irritable bowel syndromean international survey of 40,000 subjects
Aliment Pharmacol Ther
Pharmacologic treatment of the irritable bowel syndromea systematic review of randomized, controlled trials
Ann Intern Med
British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome
Gut
Treatment of irritable bowel syndromea review of randomised controlled trials
Gut
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
Aliment Pharmacol Ther
Current concepts of the irritable bowel syndrome
Scand J Gastroenterol
Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome
BMJ
The role of psychological and biological factors in post-infective gut dysfunction
Gut
Increased risk of irritable bowel syndrome after bacterial gastroenteritiscohort study
BMJ
Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome
Gut
The infectious intestinal disease study of Englanda prospective evaluation of symptoms and health care use after an acute episode
Epidemiol Infect
Increased mast cells in the irritable bowel syndrome
Neurogastroenterol Motil
Interleukin 10 genotypes in irritable bowel syndromeevidence for an inflammatory component?
Gut
Cited by (1239)
Dietary Interventions and Brain–Gut Disorders
2024, The Gut-Brain Axis, Second EditionEvaluation of the efficacy of probiotics as treatment in irritable bowel syndrome
2024, Endocrinologia, Diabetes y NutricionFecal bacterial microbiota in constipated patients before and after eight weeks of daily Bifidobacterium infantis 35624 administration
2023, Revista de Gastroenterologia de MexicoReview - Sporeforming probiotic bacteria: Characteristics, health benefits, and technological aspects for their applications in foods and beverages
2023, Trends in Food Science and TechnologyStress, inflammation, microbiome and depression
2023, Pharmacology Biochemistry and Behavior
Supported in part by Science Foundation Ireland in the form of a centre grant (Alimentary Pharmabiotic Centre), the Health Research Board of Ireland, the Higher Education Authority of Ireland, and the European Union (PROGID QLK-2000-00563). The authors are affiliated with a multidepartmental university campus company (Alimentary Health Ltd) that investigates host-flora interactions and the therapeutic manipulation of these interactions in various human and animal disorders. The content of this report was neither influenced nor constrained by this fact.